| Literature DB >> 29855780 |
Jamal H Mahar1, Ihab Haddadin2, Divyajot Sadana3, Abishek Gadre4, Natalie Evans5, Deborah Hornacek5, Natalia Fendrikova Mahlay5, Marcelo Gomes5, Douglas Joseph5, Maya Serhal5, Michael Zhen-Yu Tong5, Seth R Bauer6, Michael Militello6, Bernard Silver7, Mehdi Shishehbor8, John R Bartholomew5, Gustavo A Heresi9.
Abstract
Management of intermediate and high risk acute pulmonary embolism (PE) is challenging. The role of multidisciplinary teams for the care of these patients is emerging. Herein, we report our experience with a pulmonary embolism response team (PERT). We conducted a retrospective chart review on all patients admitted to the Cleveland Clinic main campus who required activation of the (PERT) from October 1, 2014 to September 1, 2016. We extracted data pertaining to clinical presentation, bleeding complications, and pre- and post-discharge imaging. Patients were classified as low, intermediate or high risk PE. Descriptive and continuous variables were collected and analyzed. There were 134 PERT activations. PE was confirmed by CT-PA in 118 patients. Fifteen (13%) patients were classified as low risk, 80 (68%) intermediate risk PE and 23 (19%) high risk PE. Fourteen (12%) patients were treated with catheter directed rtPA, 6 (5%) received full dose (100 mg rtPA), 16 (13%) received systemic half-dose (50 mg rtPA), 6 (5%) underwent a surgical embolectomy and 4 (3%) underwent mechanical thrombectomy. 65 (55%) patients received anticoagulation only, and 8 (7%) patients were managed conservatively without any anticoagulation or advanced therapy. 11 (9%) patients died while during the hospitalization. Fourteen patients had major bleeding events. There were no bleeding events among patients who received systemic low dose or full dose rtPA. A multidisciplinary approach to cases of intermediate risk and high risk PE can be implemented successfully. We saw a relatively low rate of bleeding events with use of rtPA.Entities:
Keywords: Anticoagulation; PERT; Pulmonary embolism; Thrombolysis
Mesh:
Substances:
Year: 2018 PMID: 29855780 DOI: 10.1007/s11239-018-1686-2
Source DB: PubMed Journal: J Thromb Thrombolysis ISSN: 0929-5305 Impact factor: 2.300